Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder (NCT07184840) | Clinical Trial Compass
RecruitingPhase 2
Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder
China110 participantsStarted 2025-09-09
Plain-language summary
Neuromyelitis optica spectrum disorder (NMOSD) is a relapsing, inflammatory autoimmune disorder of the central nervous system characterized by the pathogenic anti-aquaporin 4 antibody (AQP4-IgG). The objectives of this study are to assess the efficacy and safety of eculizumab for treatment of patients with neuromyelitis optica spectrum disorders during acute phase who are anti-aquaporin-4 (AQP4) antibody-positive. Eculizumab, a humanized monoclonal antibody, inhibits the terminal complement protein C5 and prevents its cleavage into C5a and the formation of C5b-9 (MAC), has approved for preventive treatment of NMOSD. Given the high efficacy of C5 inhibition, eculizumab is proposed to potentially provide rapid relief from astrocyte destruction by reducing MAC formation, which could contribute to the fast alleviation of neurological deficit during NMO acute attack. The potential of eculizumab warrants further investigation as a treatment for acute neuromyelitis optica spectrum disorders attacks.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Anti-AQP4 antibody seropositive.
✓. Male or female patients ≥18 years old
✓. Body weight ≥ 35 kg
✓. Acute optic neuritis and/or transverse myelitis enrolled within 28 days from the attack, with a change in neurological exam that meet an increase of OSIS at least 2 points of baseline compared to that of prior attack.
✓. A female subject is eligible to enter the trial if she is:
Exclusion criteria
✕. Use of IVIg within 3 weeks prior to screening
✕. Unresolved meningococcal infection
✕. Any systemic bacterial or other infection which is clinically significant in the opinion of the Investigator and has not been treated with appropriate antibiotics
✕. Participation in any other investigational drug study or was exposed to an investigational drug or device within 30 days of screening.
What they're measuring
1
Proportion of improvement in OSIS from baseline to Day 28 by 2 points or more
Timeframe: Acute attack to Day 28
Trial details
NCT IDNCT07184840
SponsorTianjin Medical University General Hospital
. Has previously received treatment with eculizumab
✕. Hypersensitivity to murine proteins or to one of the excipients of eculizumab
✕. Any medical condition that, in the opinion of the Investigator, might interfere with thepatient's participation in the trial, poses any added risk for the patient, or confounds the assessment of the patients